research Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
Certain medications, especially nervous system drugs, can cause insomnia, with risks varying by age and gender.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Monoolein-alginate beads as a platform to promote adenosine cutaneous localization and wound healing
Monoolein-alginate beads help heal wounds by controlling moisture and effectively delivering adenosine to the skin.
research New Nonsteroidal Molecules as Blockers of the Steroidogenic Pathway
New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
research Internal medicine-important advances in clinical medicine: percutaneous transluminal coronary angioplasty.
research Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents
Some minoxidil combinations can help differentiate leukemia cells without harming other cells.
research K ATP Channels and Cardiovascular Disease
K_ATP channel gene mutations are linked to heart diseases, but more research is needed to understand the connection and treatment potential.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research 1394 Long non-coding RNA AL136131.3 inhibits hair growth through mediating glycolysis in androgenetic alopecia
AL136131.3 slows hair growth by affecting energy processes in hair loss.
research Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss
A woman developed swelling in her body after taking low-dose oral minoxidil for hair loss, but it resolved after stopping the medication.
research Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study
Using electronic health records can help identify drug side effects but has some limitations.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data
Low-dose oral minoxidil is a safe treatment for hair loss, with the main side effect being excessive hair growth. Other side effects like foot swelling, low blood pressure when standing, and heart rate changes are rare.
research Synergistic therapeutic effect of ginsenoside Rg3 modified minoxidil transfersomes (MXD-Rg3@TFs) on androgenic alopecia in C57BL/6 mice
Ginsenoside Rg3 combined with minoxidil was more effective in treating hair loss in mice.
research Radioimmunoassay of Minoxidil in Human Serum
Minoxidil levels measured in human blood.
research Efficacy and Safety of Sirolimus for Blue Rubber Bleb Nevus Syndrome: A Prospective Study
Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.
research Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review
The safety and tolerability of low-dose oral minoxidil for treating hair loss in adolescents is not clearly determined.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Minoxidil — An Alternative to Nephrectomy for Refractory Hypertension
Minoxidil effectively lowers blood pressure with few side effects.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
research Peritoneal reactions with some of the tubal occlusive agents.
GRF is not safe for tubal occlusion.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
research Allopregnanolone-mediated protective effects of progesterone on tributyltin-induced neuronal injury in rat hippocampal slices
Progesterone protects neurons from damage by converting to allopregnanolone, which works through GABAA receptors.
research Efficacy of adipose stromal cells-enriched high-density fat graft combined with BTX-A for Raynaud’s phenomenon: a prospective cohort study
Combining fat grafts with botulinum toxin helps improve Raynaud's symptoms.
research The Pharmacologic Basis of the Cardiovascular Toxicity of Minoxidil in the Dog
Minoxidil can harm dog's heart.
research Wedelolactone: A Natural Anti-inflammatory Coumarin Derivative
Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]
Minoxidil 0.25 mg with spironolactone 25 mg reduces hair loss and improves hair density in women.
research Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.